ERYTECH PHARMA's ticker is ERYP and the CUSIP is 29604W108. A total of 10 filers reported holding ERYTECH PHARMA in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $8,810 | +29266.7% | 12,069 | -60.8% | 0.00% | – |
| Q1 2023 | $30 | -100.0% | 30,802 | +184.5% | 0.00% | – |
| Q4 2020 | $106,000 | +10.4% | 10,826 | -29.4% | 0.00% | – |
| Q3 2020 | $96,000 | -25.6% | 15,342 | 0.0% | 0.00% | – |
| Q2 2020 | $129,000 | +57.3% | 15,342 | 0.0% | 0.00% | – |
| Q1 2020 | $82,000 | -26.8% | 15,342 | 0.0% | 0.00% | – |
| Q4 2019 | $112,000 | +43.6% | 15,342 | -12.7% | 0.00% | – |
| Q3 2019 | $78,000 | -44.3% | 17,582 | -10.2% | 0.00% | – |
| Q2 2019 | $140,000 | -18.6% | 19,582 | -13.7% | 0.00% | – |
| Q1 2019 | $172,000 | +9.6% | 22,682 | -4.2% | 0.00% | – |
| Q4 2018 | $157,000 | -47.5% | 23,682 | -30.9% | 0.00% | – |
| Q3 2018 | $299,000 | -32.7% | 34,248 | -10.9% | 0.00% | -100.0% |
| Q2 2018 | $444,000 | -49.2% | 38,448 | -7.6% | 0.00% | 0.0% |
| Q1 2018 | $874,000 | -8.9% | 41,630 | -4.4% | 0.00% | 0.0% |
| Q4 2017 | $959,000 | – | 43,567 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 1,314,656 | $690,000 | 0.03% |
| Vanguard Personalized Indexing Management, LLC | 59,839 | $33,000 | 0.00% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 11,005 | $6,000 | 0.00% |
| Asset Dedication, LLC | 4,000 | $2,000 | 0.00% |
| Ikarian Capital, LLC | 3,019 | $2,000 | 0.00% |
| UBS Group AG | 4,320 | $2,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 10,590 | $6,000 | 0.00% |
| Mariner, LLC | 59,472 | $33,000 | 0.00% |
| Citadel Advisors | 18,181 | $10,000 | 0.00% |